Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI platform to optimize clinical trial design, patient identification, and data collection, aiming for improved outcomes and efficiency. The company is well-capitalized with $287 million in cash and strong backing from top-tier life science VCs, positioning it for robust pipeline advancement.